Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus XOFLUZA.
ADEFOVIR DIPIVOXIL vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
10 mg orally once daily on an empty stomach.
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category C
Category C
Antiviral
Antiviral